Factors linked to virological failure in people on a dolutegravir-based regimen in Mamelodi.

Background: Since 2019, the World Health Organization has recommended dolutegravir-containing regimens for HIV in low- and middle-income countries because of its high genetic barriers to resistance, lower drug interactions, fewer side effects, higher viral load (VL) suppression rates and cost-effectiveness compared to efavirenz.

Objectives: This study investigates factors associated with unsuppressed VLs in people living with HIV on tenofovir-lamivudine and dolutegravir (TLD) in South Africa (SA).

Method: A cross-sectional study was conducted between October 2023 and February 2024 at Mamelodi Regional Hospital's Ntshembo Clinic.